Pharmaceuticals Updated Clinical Data for Omicron BA.4/BA.5 – Pfizer and BioNTechBy AndyNovember 7, 20220 Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared…
Pharmaceuticals Omicron BA.4/BA.5 – adapted bivalent vaccineBy AndyOctober 13, 20220 Pfizer Inc. and BioNTech SE has announced early data from a Phase 2/3 clinical trial evaluating the safety, tolerability, and immunogenicity of…
